Dynorphin Uses a Non-opioid Mechanism to Potentiate N-methyl-D-aspartate Currents in Single Rat Periaqueductal Gray Neurons
Overview
Affiliations
The interaction of the endogenous K-opioid, dynorphin, with N-methyl-D-aspartate (NMDA) receptors was studied in single periaqueductal gray (PAG) cells using the whole cell patch recording technique. We have found that dynorphin A (1-17) rapidly and reversibly potentiates NMDA-activated currents in a subpopulation of PAG cells. The potentiation cannot be blocked by the non-specific opioid antagonist, naloxone, nor can it be reversed by the specific kappa-opioid antagonist, nor-BNI. In addition, the non-opioid fragment of dynorphin, dynorphin A (2-17), is effective in potentiating NMDA currents, while the specific kappa-opioid, U50,488, cannot mimic the action of dynorphin A (1-17). The non-opioid dynorphin action and the rapid onset and recovery of the potentiation are consistent with the idea that dynorphin interacts directly with NMDA receptors in PAG cells.
Morrison S, Cano G, Hernan S, Chiavetta P, Tupone D Curr Biol. 2024; 35(1):59-76.e4.
PMID: 39626667 PMC: 11706707. DOI: 10.1016/j.cub.2024.11.006.
Best K, Mojena M, Barr G, Schmidt H, Cohen A J Neurotrauma. 2021; 39(1-2):1-19.
PMID: 34751584 PMC: 8978570. DOI: 10.1089/neu.2021.0063.
Spinocerebellar ataxia type 23 (SCA23): a review.
Wu F, Wang X, Li X, Teng H, Tian T, Bai J J Neurol. 2020; 268(12):4630-4645.
PMID: 33175256 DOI: 10.1007/s00415-020-10297-5.
Mechanism and site of action of big dynorphin on ASIC1a.
Borg C, Braun N, Heusser S, Bay Y, Weis D, Galleano I Proc Natl Acad Sci U S A. 2020; 117(13):7447-7454.
PMID: 32165542 PMC: 7132280. DOI: 10.1073/pnas.1919323117.
Opioids Resistance in Chronic Pain Management.
Morrone L, Scuteri D, Rombola L, Mizoguchi H, Bagetta G Curr Neuropharmacol. 2017; 15(3):444-456.
PMID: 28503117 PMC: 5405610. DOI: 10.2174/1570159X14666161101092822.